ADAPTIMMUNE THERAPEUTICS PLC's ticker is ADAP and the CUSIP is 00653A107. A total of 89 filers reported holding ADAPTIMMUNE THERAPEUTICS PLC in Q4 2020. The put-call ratio across all filers is 0.77 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $23,270 | -15.7% | 29,833 | 0.0% | 0.00% | – |
| Q2 2023 | $27,598 | -15.1% | 29,833 | 0.0% | 0.00% | – |
| Q1 2023 | $32,518 | -27.4% | 29,833 | -2.8% | 0.00% | – |
| Q4 2022 | $44,798 | +40.0% | 30,683 | +3.9% | 0.00% | – |
| Q3 2022 | $32,000 | -36.0% | 29,533 | -0.4% | 0.00% | – |
| Q2 2022 | $50,000 | -18.0% | 29,654 | 0.0% | 0.00% | – |
| Q1 2022 | $61,000 | -57.3% | 29,654 | -22.3% | 0.00% | – |
| Q4 2021 | $143,000 | -37.6% | 38,154 | -13.7% | 0.00% | – |
| Q3 2021 | $229,000 | +23.8% | 44,197 | +2.0% | 0.00% | – |
| Q2 2021 | $185,000 | +3.9% | 43,349 | +29.0% | 0.00% | – |
| Q1 2021 | $178,000 | +7.9% | 33,613 | +9.8% | 0.00% | – |
| Q4 2020 | $165,000 | -87.6% | 30,626 | -81.6% | 0.00% | -100.0% |
| Q3 2020 | $1,328,000 | +762.3% | 166,465 | +978.6% | 0.00% | – |
| Q2 2020 | $154,000 | -87.4% | 15,434 | -83.0% | 0.00% | -100.0% |
| Q3 2018 | $1,222,000 | – | 90,856 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Syncona Portfolio Ltd | 1,377,294 | $1,501,250 | 2.44% |
| NEA Management Company, LLC | 17,079,779 | $18,616,958 | 1.29% |
| Endurant Capital Management LP | 1,660,835 | $1,810,310 | 0.93% |
| Matrix Capital Management Company, LP | 38,974,185 | $42,481,862 | 0.58% |
| Long Focus Capital Management, LLC | 5,435,439 | $5,924,629 | 0.34% |
| PFM Health Sciences, LP | 5,992,571 | $6,531,902 | 0.29% |
| Key Client Fiduciary Advisors, LLC | 321,155 | $350,059 | 0.22% |
| DAFNA Capital Management LLC | 351,064 | $382,660 | 0.12% |
| Rock Springs Capital Management LP | 2,787,845 | $3,038,751 | 0.07% |
| Baker Brothers Advisors | 9,830,877 | $10,715,656 | 0.06% |